Veterinary
Oncology Market Size, Share, Trends, Analysis Report – 2035

The global veterinary oncology market reached USD 2 billion in 2025
and is projected to rise from USD 2.2 billion in 2026 to USD 5.4 billion by
2035, registering a CAGR of 10.3% from 2026 to 2035, according to Global Market
Insights Inc. Growth reflects increasing demand for cancer diagnosis and
treatment among companion animals, supported by improving specialist care
access and an expanding range of therapeutic options. As veterinary practices
strengthen their diagnostic capabilities, the market is evolving from episodic
intervention toward more comprehensive cancer management spanning screening,
staging, treatment, and follow-up.

Rising prevalence and incidence of cancer in animals are central to
this expansion. Longer companion animal lifespans increase exposure to
age-associated malignancies, while more pet owners seek specialist referrals
rather than limiting care to symptom management. Common conditions including
lymphoma, mast cell tumors, mammary tumors, and osteosarcoma create recurring
demand for diagnostic workups and multidisciplinary treatment. Better awareness
of available therapies also supports higher engagement with oncology services,
particularly in markets with established veterinary referral networks.

Technological advancements in pet cancer diagnosis represent another
important growth driver. High-resolution imaging, digital radiography, MRI, and
minimally invasive biopsy techniques help clinicians characterize tumors and
plan treatment more precisely. Molecular testing and emerging liquid biopsy
approaches offer additional opportunities to refine staging and monitor disease
progression. AI-assisted image and pathology interpretation can also improve
the efficiency of specialist diagnostic workflows, potentially extending
advanced evaluation beyond university hospitals into private veterinary
practices.

Growing research and investment in pet cancer therapy are broadening
the commercial landscape. Comparative oncology programs connect naturally
occurring cancers in companion animals with translational research, supporting
work on targeted agents, immunotherapies, cancer vaccines, and new treatment
protocols. Partnerships between academic centers and animal health companies
are helping advance clinical validation. However, the high cost of complex
treatment and adverse effects associated with oncology medicines remain
barriers that influence pet owners’ decisions and the uptake of advanced
procedures.

By cancer diagnostics and treatment, diagnostics accounted for 43.9%
of the market in 2025. Imaging and biopsy are important components of
diagnostic revenue, with CT and MRI supporting staging and treatment planning
while cytology and histopathology help identify tumor characteristics. Demand
is being reinforced by specialist centers that require dependable pre-treatment
assessment and by general veterinary clinics seeking better access to referral
laboratory services. Greater diagnostic precision can support appropriate
treatment selection and ongoing monitoring throughout the care pathway.

By animal type, the canine segment represented 61.4% of global
veterinary oncology revenue in 2025. Dogs account for a substantial proportion
of oncology referrals and treatment activity, reflecting the prevalence of
cancer in aging canine populations and the availability of established
treatment protocols. Canine oncology also benefits from a relatively developed
commercial pipeline of targeted therapies and from clinical research addressing
lymphoma, mast cell tumors, and osteosarcoma. These factors position canine
care as a major contributor to specialist service utilization and therapeutic
demand.

Browse
complete summary of this research report @ https://www.gminsights.com/industry-analysis/veterinary-oncology-market

North America led the veterinary oncology market with a 49.8% share
in 2025. The region benefits from established referral hospitals,
board-certified specialists, veterinary diagnostic laboratories, and regulatory
pathways for animal oncology medicines. Academic veterinary centers contribute
to clinical evidence and treatment standards, while private specialty networks
expand access to advanced imaging, chemotherapy, and precision radiation
procedures. Asia Pacific is emerging as a faster-growing regional opportunity
as companion animal ownership and veterinary service capacity increase.

Zoetis led the veterinary oncology market with over 19% share in
2025. Its position is supported by Palladia, a targeted therapy used in canine
mast cell tumor treatment, and established relationships with veterinary
practices. Competition extends beyond pharmaceuticals into diagnostic testing,
radiation equipment, and specialist oncology services. Market participants are
emphasizing targeted therapeutic development, diagnostic integration, and
dependable clinical workflows as providers seek to improve treatment selection
and outcomes.

Some of the major players in this market are Boehringer Ingelheim
International, Elanco Animal Health, Merck Animal Health, IDEXX Laboratories,
AB Science, Siemens Healthineers (Varian Medical Systems), Accuray, Elekta,
PetCure Oncology, Virbac, Dechra Pharmaceuticals, and Nippon Zenyaku Kogyo
(ZENOAQ). Their participation spans animal health pharmaceuticals, pathology
and imaging services, radiation systems, and specialty treatment delivery.
Differentiation increasingly depends on clinical evidence, product
accessibility, practitioner support, and the ability to serve multiple stages
of veterinary oncology care.

Chapter 1 Methodology & Scope

1.1 Research approach

1.2 Quality commitments

1.2.1 GMI AI policy & data integrity commitment

1.2.1.1 Source consistency protocol

1.3 Research trail & confidence scoring

1.3.1 Research trail components

1.3.2 Scoring components

1.4 Data collection

1.4.1 Partial list of primary sources

1.5 Data mining sources

1.5.1 Paid sources

1.5.1.1 Sources, by region

1.6 Base estimates and calculations

1.6.1 Base year calculation for any one approach

1.7 Market estimates & forecasts parameters

1.8 Forecast model

1.8.1 Quantified market impact analysis

1.8.1.1 Mathematical impact of growth parameters on forecast

1.9 Research transparency addendum

1.9.1 Source attribution framework

1.9.2 Quality assurance metrics

1.9.3 Our commitment to trust

Chapter 2 Executive Summary

2.1 Industry 360°synopsis

2.1.1 Business trends

2.1.2 Cancer diagnostics & treatment trends

2.1.3 Animal type trends

2.1.4 Cancer type trends

2.1.5 Regional trends

2.2 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis

3.2 Industry impact forces

3.2.1 Growth drivers

3.2.1.1 Rising prevalence and incidence of cancer in animals

3.2.1.2 Technological advancements in pet cancer diagnosis

3.2.1.3 Growing research and investments in pet cancer therapy

3.2.1.4 Increasing pet insurance adoption

3.2.2 Industry pitfalls and challenges

3.2.2.1 High cost of cancer treatment and procedures

3.2.2.2 Adverse effects of drugs used for pet cancer treatment

3.2.3 Market opportunities

3.2.3.1 Development of personalized and targeted oncology therapies

3.2.3.2 Expansion of veterinary oncology infrastructure and
specialty clinics

3.3 Growth potential analysis

3.4 Technology and innovation landscape

3.4.1 Current technological trends

3.4.2 Emerging technologies

3.5 Pricing trend analysis (Driven by primary research)

3.6 Regulatory landscape (Driven by primary research)

3.6.1 North America

3.6.2 Europe

3.6.3 Asia Pacific

3.6.4 Latin America

3.6.5 MEA

3.7 Porter's analysis

3.8 PESTEL analysis

3.9 Patent analysis

3.10 Future market trends

3.11 Impact of AI and Generative AI on the market (Driven by primary
research)

3.12 Investment & funding analysis (Driven by primary research)

3.13 Pet population statistics (Driven by primary research)

About
Global Market Insights

Global Market Insights Inc., headquartered
in Delaware, U.S., is a global market research and consulting service provider,
offering syndicated and custom research reports along with growth consulting
services. Our business intelligence and industry research reports offer clients
penetrative insights and actionable market data specially designed and
presented to aid strategic decision making. These exhaustive reports are
designed via a proprietary research methodology and are available for key
industries such as chemicals, advanced materials, technology, renewable energy,
and biotechnology.

Contact Us